All In Biotech

Drug Trial Radar · NCT06308926

MRG-001 as an Immunoregulatory and Regenerative Therapy for ARDS Patients

A Phase IIa, Double-Blind, Randomized, Multi-Center Study Comparing MRG-001 to Placebo in Patients With Acute Respiratory Distress Syndrome

Last checked: Nov 20, 2026Latest source record: Aug 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

60

Planned (sponsor's estimate)

Start

Dec 1, 2024

Primary completion

Feb 1, 2026

Study completion Jul 1, 2026

Sponsor

Lead sponsor
MedRegen LLCIndustry
Sponsor type
Industry
Collaborators
Vanderbilt University Medical Center
First posted
Mar 13, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a phase IIa, dose-ranging, proof-of-concept study of MRG-001 in patients with ARDS. The aim is to determine the safety and preliminary efficacy of MRG-001 across two dose ranges.

Conditions

  • Acute Respiratory Distress Syndrome
  • Respiratory Failure
  • Respiratory Distress Syndrome
  • Respiratory Tract Diseases
  • Cytokine Storm

Interventions

  • MRG-001 (Low-dose)Drug

    MRG-001 is subcutaneously administered.

  • MRG-001 (High-dose)Drug

    MRG-001 is subcutaneously administered.

  • PlaceboOther

    Saline placebo will be administered subcutaneously based on bodyweight and similar dose as the treatment group.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Hemopoietic stem cell mobilizationTime frame: 24 Hours
  2. Organ FailureTime frame: 28 Days

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.